Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Malignancy.
Status:
Unknown status
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
Phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and
safety of Hetrombopag in subjects with chemotherapy-induced thrombocytopenia receiving
chemotherapy for the treatment of solid tumors and lymphomas.